

FORMATO EUROPEO PER
CURRICULUM VITAE



**INFORMAZIONI
PERSONALI**

Luigi Schips

-omissis-

POSIZIONE ATTUALE

Novembre 2021 - attuale
Direttore Scuola di Specializzazione in Urologia
Università degli Studi "G. d'Annunzio" di Chieti e Pescara

Maggio 2020 - attuale
Professore I Fascia di Urologia (MED/24)
Università degli Studi "G. d'Annunzio" di Chieti e Pescara
Gennaio 2017 – Attuale
Direttore Unità Operativa Complessa Urologia Aziendale
ASL 02 Abruzzo – Lanciano Vasto Chieti

**PRECEDENTI ESPERIENZE
LAVORATIVE**

Febbraio 2013 – Ottobre 2013
Direttore ad interim UOC Clinica Urologica di Chieti
ASL 02 Abruzzo – Lanciano Vasto Chieti
Agosto 2021 – Febbraio 2023
Commissario Abilitazione Scientifica Nazionale (2021-2023)
06/E2 Chirurgia Plastica-Ricostruttiva, Chirurgia Pediatrica E Urologia
Febbraio 2013 – Ottobre 2017
Referente Chirurgia Urologica Robotica
ASL 02 Abruzzo – Lanciano Vasto Chieti
Aprile 2007 – Ottobre 2017
Direttore UOC Urologia
Ospedale di Vasto
Marzo 2004 – Marzo 2007
Professore associato di Urologia
Universitätsklinik für Urologie GRAZ (AUSTRIA)

**ISTRUZIONE E
FORMAZIONE**

16 Gennaio 1995 - 15 Gennaio 2001
Specializzazione in Urologia presso Universitätsklinik fuer Urologie in Graz
(AUSTRIA)
1992: Abilitazione all'esercizio della professione medica
Università degli Studi "G. d'Annunzio" - Chieti
26 Marzo 1992:
Laurea in Medicina e Chirurgia
Università degli Studi "G.D'Annunzio" – Chieti

**TRAINING
PROFESSIONALE E**

15 Ottobre 2001 – 19 Ottobre 2001
Corso base e avanzato di Laparoscopia presso Ethicon Endosurgery Institute di

SCOLARSHIP

Norderstedt (Amburgo)
Settembre 2001
Corso “SPARC” (Intervento per l’Incontinenza da stress)
4 Marzo 2002 – 7 Marzo 2002
Corso di Laparoscopia Urologica presso Ethicon Endosurgery - Institute di
Norderstedt (Amburgo)
Febbraio 2004
Corso Prostatectomia Radicale Laparoscopica Extraperitoneale presso il Prof. Dr.
J.U.Stolzenburg Clinica Urologica Università di Lipsia (Germania)

ASSOCIAZIONE A SOCIETÀ SCIENTIFICHE

Novembre 2021 - Oggi
Delegato Regionale (Abruzzo e Molise) della Società Italiana di Urologia
2003 – Oggi
European Association of Urology (EAU)
2002 – Oggi
Associazione Urologi Ospedalieri (AURO)
2002 – Oggi
Società Italiana di Urologia Oncologica (SIUrO)
1999 – Oggi
Österreichischen Gesellschaft für Urologie (ÖGU)
1998 – Oggi
Deutschen Gesellschaft für Urologie (DGU)
1997 – Oggi
Società Italiana di Urologia (SIU)

STUDI CLINICI FINANZIATI (Principal Investigator o Sub- investigator)

2010-2011
FDC tamsulosin/solifenacin.
EudraCT number 2008-001212-20. Sponsor Astellas
2012-2022
ABITUDE
NCT01715285. Sponsor: Jansenn
2009-2013
PAUSE study
NCT01021670. Sponsor: Jansenn
2016-2019
PLUS study
NCT02757768. Sponsor: Astellas
2014-2019
ARAMIS
NCT02200614. Sponsor: Bayer
2018-ongoing
PROTEUS
NCT03767244. Sponsor: Jansenn
2018-ongoing
ANNAR
Sponsor: Jansenn
2020-ongoing
KEYNOTE-001
Sponsor: Merck Sharp & Dohme Corp
2022-ongoing
SunRise 3
Sponsor: Jansenn
2022-ongoing
VAC52416BAC3001- Embrace

INDICI BIBLIOMETRICI

Fonte: SCOPUS (02/12/22)

Sponsor: Jansenn

H-Index: 40

Articoli: 217

Citazioni: 4723

ATTIVITÀ EDITORIALE

Reviewer

European Urology

Minerva Urologica e Nefrologica

Frontiers in Oncology

Editorial Board

Archivio Italiano di Anrologia e Urologia

DOCENZE E TUTORAGGIO

Novembre 2010 - Tutor per la Chirurgia Laparoscopica Renale presso Reparto Urologia Cottolengo Torino

Ottobre 2010 - Tutor per la Chirurgia Laparoscopica Renale presso Reparto Urologia Tradate (Varese)

Luglio 2009 - Tutor per la Chirurgia Robotica Laparoscopica Renale presso Istituto Europeo di Oncologia (IEO) di Milano

Luglio 2007 - Tutor per la Chirurgia Laparoscopica presso la Clinica Urologica Università Federico II di Napoli

2013 - Tutor per la Chirurgia Robotica Laparoscopica Renale presso la Clinica Urologica Università Statale di Milano

PREMI E RICONOSCIMENTI

Ottobre 2016

Premio “Bracci” Conferito dalla Società Italiana di Urologia

Giugno 2011

Premio Nazionale Rocchetta Congresso Nazionale SIURO Napoli

Ottobre 2010

Premio Massimino D’Armiento Congresso Nazionale SIU Milano

Aprile 2009

Primo intervento di Nefrectomia Parziale in assenza di ischemia con tecnica SINGLE PORT eseguita in Europa

Febbraio 2009

2° premio “SINGLE PORT LAPAROSCOPY NEPHRECTOMY AND ADRENALECTOMY: INITIAL EXPERIENCE WITH MULTICHANNEL TROCAR” al 2nd World Congress on Controversies in Urology (CURy) Lisbon, Portugal, February 5- 8, 2009

Ottobre 2008

Primo Report al mondo di Surrenalectomia con Tecnica SINGLE PORT

Ottobre 2008

Primo Intervento di Nefrectomia con Tecnica SINGLE PORT in ITALIA

Luglio 2008

Primo Intervento di Nefrectomia con Tecnica S.I.L.S. effettuata in Italia

Giugno 2006

3° Premio Miglior Video CONGRESSO NAZIONALE SIU: “L'UTILIZZO DELLA COLLA DI FIBRINA AUTOLOGA PER L'EMOSTASI NELLA NEFRECTOMIA PARZIALE VIDEOLAPAROSCOPICA”

Marzo 2005

III Miglior abstract XX Congresso EAU Istanbul 16-19 marzo 2005 “Comparison of predictive accuracy of four prgnostic models for nonmetastatic renal cell carcinoma after nephrectomy. A European multicentre study”.

RICERCA FINANZIATA

2018-2021: Ricercatore nel Progetto: “Sviluppo di Piattaforme Meccatroniche, genomiche e bionformatiche per oncologia di precisione”- Acronimo: PMGB- Codice progetto: ARS01_01195
 Dal 2022: Ricercatore del progetto vincitore del PON-MISE (decreto del 09/2022 n.° 2650). Progetto n. 21-F/180021/03/X43

ATTIVITÀ CLINICA

Direttore della UOC di Urologia di Vasto dal 2007, dal 2017 è direttore della UOC Aziendale di Urologia della ASL Lanciano Vasto Chieti risultato della fusione di tre distinte unità operative sul territorio della ASL (Chieti, Lanciano e Vasto). La UOC conta 36 posti di degenza in regime ordinario nei P.O. di Chieti e Vasto e un servizio di chirurgia ambulatoriale nel P.O. di Lanciano. Nel complesso vengono eseguiti circa 2000 interventi chirurgici l'anno con ricovero ordinario, di cui circa 1500 di chirurgia maggiore.

Attualmente sono in attesa di intervento chirurgico circa 3000 pazienti, di questi circa 1300 con priorità di classe A. Di questi circa 110 pazienti con diagnosi di carcinoma prostatico, 100 con diagnosi di neoplasia renale e 130 per neoplasie vescicali (di cui 15 in attesa di cistectomia radicale).

PUBBLICAZIONI SCIENTIFICHE

- [1] Aliberti A, Bada M, Rapisarda S, Natoli C, Schips L, Cindolo L. Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: A retrospective, single-center study. *Minerva Urologica e Nefrologica* 2019;71:181–4. <https://doi.org/10.23736/S0393-2249.18.03109-0>.
- [2] Altziebler S, Galle G, Schips L, Zigeuner R. Suprapubic catheter in the multiply injured patient. *European Surgery* 2002;34:19–20. <https://doi.org/10.1007/BF02947623>.
- [3] Anele UA, Marchioni M, Yang B, Simone G, Uzzo RG, Lau C, et al. Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA Collaborative Group). *World Journal of Urology* 2019;37:2439–50. <https://doi.org/10.1007/s00345-019-02657-2>.
- [4] Antonaci A, Fasanella D, Galica V, Tinari N, Giampietro J, Di Marino P, et al. Retroperitoneal extension of massive ulcerated testicular seminoma through the inguinal canal: A case report. *Archivio Italiano Di Urologia e Andrologia* 2021;93:64–7. <https://doi.org/10.4081/AIUA.2021.1.64>.
- [5] Antonelli A, Cindolo L, Sandri M, Annino F, Carini M, Celia A, et al. Predictors of the Transition from off to on Clamp Approach during Ongoing Robotic Partial Nephrectomy: Data from the CLOCK Randomized Clinical Trial. *Journal of Urology* 2019;202:62–7. <https://doi.org/10.1097/JU.000000000000194>.
- [6] Antonelli A, Cindolo L, Sandri M, Annino F, Carini M, Celia A, et al. Reply by Authors. *The Journal of Urology* 2019;202:68. <https://doi.org/10.1097/01.JU.0000557722.09229.13>.
- [7] Antonelli A, Cindolo L, Sandri M, Bertolo R, Annino F, Carini M, et al. Safety of on- vs off-clamp robotic partial nephrectomy: per-protocol analysis from the data of the CLOCK randomized trial. *World Journal of Urology* 2020;38:1101–8. <https://doi.org/10.1007/s00345-019-02879-4>.
- [8] Antonelli A, Cindolo L, Sandri M, Veccia A, Annino F, Bertagna F, et al. Is off-clamp robot-assisted partial nephrectomy beneficial for renal function? Data from the CLOCK trial. *BJU International* 2022;129:217–24. <https://doi.org/10.1111/bju.15503>.
- [9] Antonelli A, Cindolo L, Sandri M, Veccia A, Annino F, Bertagna F, et al. The role of warm ischemia time on functional outcomes after robotic partial nephrectomy: a radionuclide renal scan study from the clock randomized trial. *World Journal of Urology* 2023;41:1337–44. <https://doi.org/10.1007/s00345-023-04366-3>.
- [10] Antonelli A, Furlan M, Sandri M, Minervini A, Cindolo L, Parma P, et al. The

- R.E.N.A.L. nephrometric nomogram cannot accurately predict malignancy or aggressiveness of small renal masses amenable to partial nephrectomy. *Clinical Genitourinary Cancer* 2014;12:366–72. <https://doi.org/10.1016/j.clgc.2014.02.003>.
- [11] Antonelli A, Mari A, Tafuri A, Tellini R, Capitanio U, Gontero P, et al. Prediction of significant renal function decline after open, laparoscopic, and robotic partial nephrectomy: External validation of the Martini's nomogram on the RECORD2 project cohort. *International Journal of Urology* 2022;29:525–32. <https://doi.org/10.1111/iju.14831>.
- [12] Antonelli A, Veccia A, Pavan N, Mir C, Breda A, Takagi T, et al. Outcomes of Partial and Radical Nephrectomy in Octogenarians – A Multicenter International Study (Resurge). *Urology* 2019;129:139–45. <https://doi.org/10.1016/j.urology.2019.03.009>.
- [13] Augustin H, Schips L, Vilits P, Zigeuner R, Petritsch HP, Uggowitz M, et al. Handicap of walking by a huge paratesticular liposarcoma. *Urologia Internationalis* 2001;66:229–30. <https://doi.org/10.1159/000056622>.
- [14] Autorino R, Kaouk JH, Yakoubi R, Rha KH, Stein RJ, White WM, et al. Urological laparoendoscopic single site surgery: Multi-institutional analysis of risk factors for conversion and postoperative complications. *Journal of Urology* 2012;187:1989–94. <https://doi.org/10.1016/j.juro.2012.01.062>.
- [15] Autorino R, Kim FJ, Rassweiler J, De Sio M, Ribal MJ, Liatsikos E, et al. Mini-laparoscopy, laparoendoscopic single-site surgery and natural orifice transluminal endoscopic surgery-assisted laparoscopy: Novice surgeons' performance and perception in a porcine nephrectomy model. *BJU International* 2012;110:E991–6. <https://doi.org/10.1111/j.1464-410X.2012.11289.x>.
- [16] Aziz A, May M, Zigeuner R, Pichler M, Chromecki T, Cindolo L, et al. Do young patients with renal cell carcinoma feature a distinct outcome after surgery? A comparative analysis of patient age based on the multinational corona database. *Journal of Urology* 2014;191:310–5. <https://doi.org/10.1016/j.juro.2013.08.021>.
- [17] Bada M, Berardinelli F, Nyirady P, Varga J, Ditunno P, Battaglia M, et al. Adherence to the EAU guidelines on Penile Cancer Treatment: European, multicentre, retrospective study. *Journal of Cancer Research and Clinical Oncology* 2019;145:921–6. <https://doi.org/10.1007/s00432-019-02864-9>.
- [18] Bada M, Castellan P, Tamburro FR, Berardinelli F, Neri F, Cindolo L, et al. Work up of incidental adrenal mass: state of the art. *Urologia* 2016;83:179–85. <https://doi.org/10.5301/uro.5000176>.
- [19] Bandini M, Marchioni M, Preisser F, Nazzani S, Tian Z, Graefen M, et al. Comprehensive analysis of in-hospital delirium after major surgical oncology procedures. *Canadian Urological Association Journal* 2020;14. <https://doi.org/10.5489/cuaj.6030>.
- [20] Bensalah K, Pantuck AJ, Crepel M, Verhoest G, Méjean A, Valéri A, et al. Prognostic variables to predict cancer-related death in incidental renal tumours. *BJU International* 2008;102:1376–80. <https://doi.org/10.1111/j.1464-410X.2008.07847.x>.
- [21] Berardinelli F, Cindolo L, De Francesco P, Proietti S, Hennessey D, Dalpiaz O, et al. The surgical experience influences the safety of retrograde intrarenal surgery for kidney stones: a propensity score analysis. *Urolithiasis* 2017;45:387–92. <https://doi.org/10.1007/s00240-016-0919-0>.
- [22] Berardinelli F, De Francesco P, Marchioni M, Cera N, Proietti S, Hennessey D, et al. Infective complications after retrograde intrarenal surgery: a new standardized classification system. *International Urology and Nephrology* 2016;48:1757–62. <https://doi.org/10.1007/s11255-016-1373-1>.
- [23] Berardinelli F, De Francesco P, Marchioni M, Cera N, Proietti S, Hennessey D, et al. RIRS in the elderly: Is it feasible and safe? *International Journal of Surgery* 2017;42:147–51. <https://doi.org/10.1016/j.ijssu.2017.04.062>.
- [24] Berardinelli F, Proietti S, Cindolo L, Pellegrini F, Pescechera R, Derek H, et al.

- A prospective multicenter european study on flexible ureterorenoscopy for the management of renal stone. *International Braz J Urol* 2016;42:479–86. <https://doi.org/10.1590/S1677-5538.IBJU.2015.0528>.
- [25] Bertolo R, Autorino R, Simone G, Derweesh I, Garisto JD, Minervini A, et al. Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). *European Urology* 2018;74:226–32. <https://doi.org/10.1016/j.eururo.2018.05.004>.
- [26] Bertolo R, Bove P, Sandri M, Cindolo L, Annino F, Leonardo C, et al. Cross-analysis of two randomized controlled trials to compare pure versus robot-assisted laparoscopic approach during off-clamp partial nephrectomy. *Minerva Urology and Nephrology* 2022;74:5–10. <https://doi.org/10.23736/S2724-6051.22.04779-6>.
- [27] Bignante G, Manfredi C, Lasorsa F, Orsini A, Licari LC, Bologna E, et al. Incidence, Timing, and Pattern of Atypical Recurrence after Minimally Invasive Surgery for Urothelial Carcinoma. *Journal of Clinical Medicine* 2024;13. <https://doi.org/10.3390/jcm13123537>.
- [28] Bindayi A, Autorino R, Capitanio U, Pavan N, Mir MC, Antonelli A, et al. Trifecta Outcomes of Partial Nephrectomy in Patients Over 75 Years Old: Analysis of the REnal SURGery in Elderly (RESURGE) Group. *European Urology Focus* 2020;6:982–90. <https://doi.org/10.1016/j.euf.2019.02.010>.
- [29] Bradshaw AW, Autorino R, Simone G, Yang B, Uzzo RG, Porpiglia F, et al. Robotic partial nephrectomy vs minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity score-matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group. *BJU International* 2020;126:114–23. <https://doi.org/10.1111/bju.15064>.
- [30] Brasseti A, Cacciamani GE, Mari A, Garisto JD, Bertolo R, Sundaram CP, et al. On-Clamp vs. Off-Clamp Robot-Assisted Partial Nephrectomy for cT2 Renal Tumors: Retrospective Propensity-Score-Matched Multicenter Outcome Analysis. *Cancers* 2022;14. <https://doi.org/10.3390/cancers14184431>.
- [31] Bravi CA, Larcher A, Capitanio U, Mari A, Antonelli A, Artibani W, et al. Perioperative Outcomes of Open, Laparoscopic, and Robotic Partial Nephrectomy: A Prospective Multicenter Observational Study (The RECORD 2 Project). *European Urology Focus* 2021;7:390–6. <https://doi.org/10.1016/j.euf.2019.10.013>.
- [32] Bravi CA, Mari A, Larcher A, Amparore D, Antonelli A, Artibani W, et al. Toward Individualized Approaches to Partial Nephrectomy: Assessing the Correlation Between Ischemia Time and Patient Health Status (RECORD2 Project). *European Urology Oncology* 2021;4:645–50. <https://doi.org/10.1016/j.euo.2020.05.009>.
- [33] Bravi CA, Mari A, Larcher A, Amparore D, Antonelli A, Artibani W, et al. Re: Toward Individualized Approaches to Partial Nephrectomy: Assessing the Correlation between Ischemia Time and Patient Health Status (RECORD2 Project). *Journal of Urology* 2022;207:925–6. <https://doi.org/10.1097/JU.0000000000002405>.
- [34] Brookman-May S, May M, Shariat SF, Xylinas E, Stief C, Zigeuner R, et al. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: Development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). *European Urology* 2013;64:472–7. <https://doi.org/10.1016/j.eururo.2012.06.030>.
- [35] Brookman-May S, May M, Shariat SF, Zigeuner R, Chromecki T, Cindolo L, et al. Prognostic effect of sarcomatoid dedifferentiation in patients with surgically treated renal cell carcinoma: A matched-pair analysis. *Clinical Genitourinary Cancer* 2013;11:465–70. <https://doi.org/10.1016/j.clgc.2013.04.026>.
- [36] Brookman-May S, May M, Zigeuner R, Shariat SF, Scherr DS, Chromecki T, et al. Collecting system invasion and fuhrman grade but not tumor size facilitate prognostic stratification of patients with pT2 renal cell carcinoma. *Journal of Urology*

- 2011;186:2175–81. <https://doi.org/10.1016/j.juro.2011.07.105>.
- [37] Brookman-May SD, May M, Wolff I, Zigeuner R, Hutterer GC, Cindolo L, et al. Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1-pT3a localized renal cell carcinoma in a comprehensive multicenter study of the CORONA project. Can we improve prognostic discrimination for patients with stage pT3a tumors? *European Urology* 2015;67:943–51. <https://doi.org/10.1016/j.eururo.2014.11.055>.
- [38] Busetto GM, Del Giudice F, Mari A, Sperduti I, Longo N, Antonelli A, et al. How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency? *Frontiers in Surgery* 2020;7. <https://doi.org/10.3389/fsurg.2020.563006>.
- [39] Calcagnile T, Sighinolfi MC, Rocco B, Assumma S, Di Bari S, Panio E, et al. Asymptomatic bacteriuria in candidates for active treatment of renal stones: results from an international multicentric study on more than 2600 patients. *Urolithiasis* 2023;51. <https://doi.org/10.1007/s00240-022-01385-4>.
- [40] Campobasso D, Marchioni M, Altieri V, Greco F, De Nunzio C, Destefanis P, et al. GreenLight Photoselective Vaporization of the Prostate: One Laser for Different Prostate Sizes. *Journal of Endourology* 2020;34:54–62. <https://doi.org/10.1089/end.2019.0478>.
- [41] Campobasso D, Marchioni M, De Nunzio C, Destefanis P, Fasolis G, Varvello F, et al. Predictors of re-intervention after greenlight laser photoselective vaporization of the prostate: multicenter long/mid-term follow-up experience. *Mini-Invasive Surgery* 2021;5. <https://doi.org/10.20517/2574-1225.2021.92>.
- [42] Campobasso D, Morselli S, Greco F, De Nunzio C, Destefanis P, Fasolis G, et al. Efficacy and safety profile of GreenLight laser photoselective vaporization of the prostate in ≥ 75 years old patients: results from the Italian GreenLight Laser Study Group. *Aging Clinical and Experimental Research* 2023;35:877–85. <https://doi.org/10.1007/s40520-023-02351-9>.
- [43] Cassani A, Marchioni M, Silletta F, D’Orta C, Primiceri G, Rizzoli A, et al. Efficacy and safety of intravesical fibrin glue instillation for management of patients with refractory hemorrhagic cystitis: 12-months results. A promising therapy for hemorrhagic cystitis. *Archivio Italiano Di Urologia e Andrologia* 2021;93:200–5. <https://doi.org/10.4081/aiua.2021.2.200>.
- [44] Castellan P, Castellucci R, Marchioni M, De Nunzio C, Tema G, Primiceri G, et al. A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer. *Expert Opinion on Drug Safety* 2019;18:759–67. <https://doi.org/10.1080/14740338.2019.1648428>.
- [45] Castellan P, Castellucci R, Schips L, Cindolo L. Safety, efficacy and reliability of 180-W GreenLight laser technology for prostate vaporization: review of the literature. *World Journal of Urology* 2015;33:599–607. <https://doi.org/10.1007/s00345-015-1490-y>.
- [46] Castellan P, Ferretti S, Litterio G, Marchioni M, Schips L. Management of Urinary Incontinence Following Radical Prostatectomy: Challenges and Solutions. *Therapeutics and Clinical Risk Management* 2023;19:43–56. <https://doi.org/10.2147/TCRM.S283305>.
- [47] Castellan P, Marchioni M, Castellucci R, De Francesco P, Iantorno R, Schips L, et al. Abiraterone acetate for early stage metastatic prostate cancer: Patient selection and special considerations. *Therapeutics and Clinical Risk Management* 2018;14:2341–7. <https://doi.org/10.2147/TCRM.S159824>.
- [48] Castellan P, Marchioni M, Rizzoli A, Di Nicola M, Porfilio I, Ghahhari J, et al. The Surgical Experience Influences the Safety and Efficacy of Photovaporization of Prostate with 180-W XPS GreenLight Laser: Comparison Between Novices vs Expert Surgeons Learning Curves. vol. 32, 2018, p. 1071–7. <https://doi.org/10.1089/end.2018.0437>.
- [49] Castellani D, Cindolo L, De Nunzio C, Di Rosa M, Greco F, Gasparri L, et al.

- Comparison Between Thulium Laser VapoEnucleation and GreenLight Laser Photoselective Vaporization of the Prostate in Real-Life Setting: Propensity Score Analysis. *Urology* 2018;121:147–52. <https://doi.org/10.1016/j.urology.2018.09.007>.
- [50] Castellucci R, Marchioni M, Fasolis G, Varvello F, Ditunno P, Di Rienzo GD, et al. The safety and feasibility of the simultaneous use of 180-W GreenLight laser for prostate vaporization during concomitant surgery. *Archivio Italiano Di Urologia e Andrologia* 2020;92:297–301. <https://doi.org/10.4081/AIUA.2020.4.297>.
- [51] Castellucci R, Primiceri G, Castellan P, Marchioni M, D'Orta C, Berardinelli F, et al. Trifecta and pentafecta rates after robotic assisted partial nephrectomy: Comparative study of patients with renal masses <4 and ≥ 4 cm. *Journal of Laparoendoscopic and Advanced Surgical Techniques* 2018;28:799–803. <https://doi.org/10.1089/lap.2017.0657>.
- [52] Cicchetti R, Basconi M, Litterio G, Mascitti M, Tamborino F, Orsini A, et al. Advances in Molecular Mechanisms of Kidney Disease: Integrating Renal Tumorigenesis of Hereditary Cancer Syndrome. *International Journal of Molecular Sciences* 2024;25. <https://doi.org/10.3390/ijms25169060>.
- [53] Cimadamore A, Calì A, Marandino L, Marletta S, Franzese C, Schips L, et al. Hot topics in renal cancer pathology: implications for clinical management. *Expert Review of Anticancer Therapy* 2022;22:1275–87. <https://doi.org/10.1080/14737140.2022.2145952>.
- [54] Cindolo L, Alvarez-Maestro M, Castellucci R, Schips L. Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. *World Journal of Urology* 2015;33:441–2. <https://doi.org/10.1007/s00345-014-1300-y>.
- [55] Cindolo L, Antonelli A, Sandri M, Annino F, Celia A, de Concilio B, et al. The role of vascular clamping during robot-assisted partial nephrectomy for localized renal cancer: Rationale and design of the CLOCK randomized phase III study. *Minerva Urologica e Nefrologica* 2019;71:96–100. <https://doi.org/10.23736/S0393-2249.18.03357-X>.
- [56] Cindolo L, Berardinelli F, Bellocci R, Schips L. Laparoendoscopic single-site unclamped nephron-sparing surgery: A case report. *European Urology* 2011;60:591–4. <https://doi.org/10.1016/j.eururo.2010.03.047>.
- [57] Cindolo L, Berardinelli F, Fanizza C, Romero M, Pirozzi L, Tamburro FR, et al. Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS. *Archivio Italiano Di Urologia e Andrologia* 2013;85:200–6. <https://doi.org/10.4081/aiua.2013.4.200>.
- [58] Cindolo L, Berardinelli F, Gidaro S, Schips L. Laparoendoscopic single-site partial nephrectomy without ischemia. *Journal of Endourology* 2010;24:1997–2002. <https://doi.org/10.1089/end.2010.0313>.
- [59] Cindolo L, Berardinelli F, Manzi A, Spagnuolo F, Fabbri E, Castellan P, et al. Intraoperative presentation of Bochdalek's hernia in an adult during robotic-assisted partial nephrectomy: An uncommon situation and literature review. *Archivio Italiano Di Urologia e Andrologia* 2015;87:327–9. <https://doi.org/10.4081/aiua.2015.4.327>.
- [60] Cindolo L, Bertolo R, Minervini A, Sessa F, Muto G, Bove P, et al. External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers. *World Journal of Urology* 2020;38:2555–61. <https://doi.org/10.1007/s00345-019-03058-1>.
- [61] Cindolo L, Castellan P, Primiceri G, Hoznek A, Cracco CM, Scoffone CM, et al. Life-Threatening complications after ureteroscopy for urinary stones: Survey and systematic literature review. *Minerva Urologica e Nefrologica* 2017;69:421–31. <https://doi.org/10.23736/S0393-2249.17.02787-4>.
- [62] Cindolo L, Castellan P, Scoffone CM, Cracco CM, Celia A, Paccaduscio A, et al. Mortality and flexible ureteroscopy: analysis of six cases. *World Journal of*

- Urology 2016;34:305–10. <https://doi.org/10.1007/s00345-015-1642-0>.
- [63] Cindolo L, Chiodini P, Brookman-May S, De Cobelli O, May M, Squillacciotti S, et al. Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: Results from a multicentre European and US study. *BJU International* 2013;112:578–84. <https://doi.org/10.1111/j.1464-410X.2012.11670.x>.
- [64] Cindolo L, Chiodini P, Gallo C, Ficarra V, Schips L, Tostain J, et al. Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. *Cancer* 2008;113:65–71. <https://doi.org/10.1002/cncr.23517>.
- [65] Cindolo L, de Francesco P, Petraghani N, Simiele F, Marchioni M, Logreco A, et al. Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study. *Minerva Urologica e Nefrologica* 2020;72:615–21. <https://doi.org/10.23736/S0393-2249.19.03595-1>.
- [66] Cindolo L, De La Taille A, Schips L, Zigeuner RE, Ficarra V, Tostain J, et al. Chromophobe renal cell carcinoma: Comprehensive analysis of 104 cases from multicenter European database. *Urology* 2005;65:681–6. <https://doi.org/10.1016/j.urology.2004.11.005>.
- [67] Cindolo L, De Nunzio C, Greco F, Destefanis P, Bergamaschi F, Ferrari G, et al. Standard vs. anatomical 180-W GreenLight laser photoselective vaporization of the prostate: a propensity score analysis. *World Journal of Urology* 2018;36:91–7. <https://doi.org/10.1007/s00345-017-2106-5>.
- [68] Cindolo L, De Nunzio C, Sountoulides P, Bantis A, Tubaro A, Schips L. The influence of ejaculation and abstinence on urinary flow rates. *Neurourology and Urodynamics* 2011;30:1571–5. <https://doi.org/10.1002/nau.21157>.
- [69] Cindolo L, Fanizza C, Romero M, Pirozzi L, Autorino R, Berardinelli F, et al. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: A record-linkage analysis. *World Journal of Urology* 2013;31:665–71. <https://doi.org/10.1007/s00345-012-1000-4>.
- [70] Cindolo L, Gidaro S, Neri F, Tamburro FR, Schips L. Assessing feasibility and safety of laparoendoscopic single-site surgery adrenalectomy: Initial experience. *Journal of Endourology* 2010;24:977–80. <https://doi.org/10.1089/end.2009.0535>.
- [71] Cindolo L, Gidaro S, Schips L. Urological applications of N.O.T.E.S. Surgical Oncology 2009;18:153–6. <https://doi.org/10.1016/j.suronc.2008.12.002>.
- [72] Cindolo L, Gidaro S, Tamburro FR, Schips L. Laparo-Endoscopic Single-Site Left Transperitoneal Adrenalectomy. *European Urology* 2010;57:911–4. <https://doi.org/10.1016/j.eururo.2009.07.001>.
- [73] Cindolo L, Gidaro S, Tamburro FR, Schips L. Reply to Riccardo Autorino, Robert J. Stein and Jihad H. Kaouk's Letter to the Editor re: Luca Cindolo, Stefano Gidaro, Fabiola R. Tamburro, Luigi Schips. Laparo-Endoscopic Single-Site Left Transperitoneal Adrenalectomy. *Eur Urol* 2010;57:911–4. *European Urology* 2010;57:e48–9. <https://doi.org/10.1016/j.eururo.2009.08.023>.
- [74] Cindolo L, Giusti G, Castellan P, Antonelli A, Schips L. Editorial Comment to Nomograms incorporating serum C-reactive protein effectively predict mortality before and after surgical treatment of renal cell carcinoma. *International Journal of Urology* 2015;22:270–270. <https://doi.org/10.1111/iju.12682>.
- [75] Cindolo L, Greco F, Fornara P, Mirone V, Schips L. Nephron sparing less: Technique and review of the current literature. *Archivos Espanoles de Urologia* 2012;65:303–10.
- [76] Cindolo L, Ingrosso M, De Francesco P, Castellan P, Berardinelli F, Fiore F, et al. Giant renal artery aneurysm: A case report. *Archivio Italiano Di Urologia e Andrologia* 2015;87:169–70. <https://doi.org/10.4081/aiua.2015.2.169>.
- [77] Cindolo L, Ingrosso M, Marchioni M, Rizzoli A, Berardinelli F, Schips L. Robot-assisted laparoscopic bladder diverticulectomy and greenlight laser anatomic

- vaporization of the prostate. *International Braz J Urol* 2018;44:403–4. <https://doi.org/10.1590/S1677-5538.IBJU.2017.0016>.
- [78] Cindolo L, Marchioni M, Emiliani E, De Francesco P, Primiceri G, Castellan P, et al. Bladder neck contracture after surgery for benign prostatic obstruction. *Minerva Urologica e Nefrologica* 2017;69:133–43. <https://doi.org/10.23736/S0393-2249.16.02777-6>.
- [79] Cindolo L, Natoli C, De Nunzio C, De Tursi M, Valeriani M, Giacinti S, et al. Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naïve Patients: An Italian Analysis of Patients' Satisfaction. *Clinical Genitourinary Cancer* 2017;15:520–5. <https://doi.org/10.1016/j.clgc.2017.04.003>.
- [80] Cindolo L, Natoli C, De Nunzio C, De Tursi M, Valeriani M, Giacinti S, et al. Safety and efficacy of abiraterone acetate in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: An Italian multicenter real life study. *BMC Cancer* 2017;17. <https://doi.org/10.1186/s12885-017-3755-x>.
- [81] Cindolo L, Patard J-J, Chiodini P, Schips L, Ficarra V, Tostain J, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: A multicenter European study. *Cancer* 2005;104:1362–71. <https://doi.org/10.1002/cncr.21331>.
- [82] Cindolo L, Pirozzi L, Fanizza C, Romero M, Sountoulides P, Roehrborn CG, et al. Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: Temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men. *International Urology and Nephrology* 2014;46:695–701. <https://doi.org/10.1007/s11255-013-0587-8>.
- [83] Cindolo L, Pirozzi L, Fanizza C, Romero M, Tubaro A, Autorino R, et al. Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-based Cohort Study. *European Urology* 2015;68:418–25. <https://doi.org/10.1016/j.eururo.2014.11.006>.
- [84] Cindolo L, Pirozzi L, Sountoulides P, Fanizza C, Romero M, Castellan P, et al. Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: Is combination therapy better than monotherapy. *BMC Urology* 2015;15. <https://doi.org/10.1186/s12894-015-0090-x>.
- [85] Cindolo L, Scoffone C, Salzano L, Autorino R, Mirone V, Schips L. Laparoendoscopic single-site (LESS) adrenalectomy and partial nephrectomy: current Italian experience with two challenging surgical procedures. *Surgical Technology International* 2010;20:240–4.
- [86] Cindolo L, Sountoulides P, Schips L. Laparoendoscopic single-site partial nephrectomy. *European Urological Review* 2011;6:132–7.
- [87] Cindolo L, Sountoulides P, Schips L. Laparoendoscopic single-site partial nephrectomy. *European Urological Review* 2012;7:140–3.
- [88] Cindolo L, Spiess PE, Bada M, Chipollini JJ, Nyirády P, Chiodini P, et al. Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study. *World Journal of Urology* 2019;37:1649–57. <https://doi.org/10.1007/s00345-018-2549-3>.
- [89] Colombo T, Augustin H, Breinl E, Schips L, Hubmer G. The use of polydimethylsiloxane in the treatment of incontinence after radical prostatectomy. *British Journal of Urology* 1997;80:923–6. <https://doi.org/10.1046/j.1464-410x.1997.00472.x>.
- [90] Colombo T, Schips L, Augustin H, Gruber H, Hebel P, Petritsch PH, et al. Value of transrectal ultrasound in preoperative staging of prostate cancer. *Minerva Urologica e Nefrologica* 1999;51:1–4.
- [91] Contieri R, Hurle R, Paciotti M, Casale P, Saita A, Porpiglia F, et al. Accuracy of

- the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG. *Minerva Urology and Nephrology* 2023;75:180–7. <https://doi.org/10.23736/S2724-6051.22.04953-9>.
- [92] Cormio L, Cindolo L, Troiano F, Marchioni M, Di Fino G, Mancini V, et al. Development and internal validation of novel nomograms based on benign prostatic obstruction-related parameters to predict the risk of prostate cancer at first prostate biopsy. *Frontiers in Oncology* 2018;8. <https://doi.org/10.3389/fonc.2018.00438>.
- [93] Corvino A, Catalano O, Faggian G, Delli Pizzi A, Tafuri D, Corvino F, et al. Multiparametric Ultrasound Diagnostic Approach to Malignancy-Mimicking Adenomatoid Tumors of the Scrotum: Is Strain Elastography Enough? *Medicina (Lithuania)* 2023;59. <https://doi.org/10.3390/medicina59071261>.
- [94] Costantini E, Di Nicola M, Marchioni M, Aielli L, Reale M, Schips L. Effects of Curcumin and Lactoferrin to Inhibit the Growth and Migration of Prostatic Cancer Cells. *International Journal of Environmental Research and Public Health* 2022;19. <https://doi.org/10.3390/ijerph192316193>.
- [95] Dalpiaz O, Gidaro S, Lipsky K, Schips L. Laparoscopic removal of 10-cm retroperitoneal liposarcoma. *Journal of Endourology* 2007;21:83–4. <https://doi.org/10.1089/end.2006.0152>.
- [96] Dalpiaz O, Primus G, Schips L. SPARC Sling System for Treatment of Female Stress Urinary Incontinence in the Elderly. *European Urology* 2006;50:826–31. <https://doi.org/10.1016/j.eururo.2006.04.016>.
- [97] Dalpiaz O, Primus G, Schips L. SPARC sling system in the treatment of female stress urinary incontinence in the elderly. vol. 16, 2006, p. 168–9.
- [98] Dalpiaz O, Primus G, Schips L. Suprapubic arc (SPARC) sling procedure in women with urodynamic urinary stress incontinence with or without low urethral closure pressure. vol. 16, 2006, p. 166–7.
- [99] De Francesco P, Ghahhari J, Castellan P, Nicolai M, De Luca G, Marchioni M, et al. Leydig cell tumor in a 53-year-old patient with gynecomastia and gynecodynia: A case report and literature review. *International Journal of Cancer Management* 2017;10. <https://doi.org/10.5812/ijcm.11572>.
- [100] De Nunzio C, Albisinni S, Freedland SJ, Miano L, Cindolo L, Finazzi Agrò E, et al. Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: A prospective multicenter italian cohort study. *Urologic Oncology: Seminars and Original Investigations* 2013;31:997–1002. <https://doi.org/10.1016/j.urolonc.2011.08.007>.
- [101] De Nunzio C, Brasseti A, Cancrini F, Prata F, Cindolo L, Sountoulides P, et al. Physical Inactivity, Metabolic Syndrome and Prostate Cancer Diagnosis: Development of a Predicting Nomogram. *Metabolites* 2023;13. <https://doi.org/10.3390/metabo13010111>.
- [102] De Nunzio C, Cindolo L, Leonardo C, Antonelli A, Ceruti C, Franco G, et al. Analysis of radical cystectomy and urinary diversion complications with the Clavien classification system in an Italian real life cohort. *European Journal of Surgical Oncology* 2013;39:792–8. <https://doi.org/10.1016/j.ejso.2013.03.008>.
- [103] De Nunzio C, Lombardo R, Baldassarri V, Cindolo L, Bertolo R, Minervini A, et al. Rotterdam mobile phone app including MRI data for the prediction of prostate cancer: A multicenter external validation. *European Journal of Surgical Oncology* 2021;47:2640–5. <https://doi.org/10.1016/j.ejso.2021.04.033>.
- [104] De Nunzio C, Nacchia A, Cicione A, Cindolo L, Gacci M, Cancrini F, et al. Physical Activity as a Protective Factor for Lower Urinary Tract Symptoms in Male Patients: A Prospective Cohort Analysis. *Urology* 2019;125:163–8. <https://doi.org/10.1016/j.urology.2018.12.035>.
- [105] de Nunzio CD, Presicce F, Pirozzi L, Castellan P, Schips L, Cindolo L, et al. The current indications and the benefits of combining a β 3-agonist with an

- anticholinergic for the treatment of OAB. *Current Drug Targets* 2015;16:1198–206. <https://doi.org/10.2174/1389450116666150806124345>.
- [106] Delli Pizzi A, Mastrodicasa D, Marchioni M, Primiceri G, Di Fabio F, Cianci R, et al. Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach. *European Radiology* 2021;31:3874–83. <https://doi.org/10.1007/s00330-020-07473-6>.
- [107] Delli Pizzi A, Mastrodicasa D, Taraschi A, Civitareale N, Mincuzzi E, Censi S, et al. Conspicuity and muscle-invasiveness assessment for bladder cancer using VI-RADS: a multi-reader, contrast-free MRI study to determine optimal b-values for diffusion-weighted imaging. *Abdominal Radiology* 2022;47:1862–72. <https://doi.org/10.1007/s00261-022-03490-9>.
- [108] Erdem S, Bertolo R, Campi R, Capitanio U, Amparore D, Anceschi U, et al. The prognostic role of histomorphological subtyping in nonmetastatic papillary renal cell carcinoma after curative surgery: is subtype really irrelevant? A propensity score matching analysis of a multi-institutional real life data. *Urologic Oncology: Seminars and Original Investigations* 2024;42:163.e1-163.e13. <https://doi.org/10.1016/j.urolonc.2024.01.028>.
- [109] Falagario UG, Lantz A, Jambor I, Busetto GM, Bettocchi C, Finati M, et al. Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors. *World Journal of Urology* 2023;41:2967–74. <https://doi.org/10.1007/s00345-023-04634-2>.
- [110] Fasanella D, Antonaci A, Esperto F, Scarpa RM, Ferro M, Schips L, et al. Potential prognostic value of miRNAs as biomarker for progression and recurrence after nephrectomy in renal cell carcinoma: A literature review. *Diagnosis* 2022;9:157–65. <https://doi.org/10.1515/dx-2021-0080>.
- [111] Fasanella D, Marchioni M, Domanico L, Franzini C, Infrerera A, Schips L, et al. Neobladder “Function”: Tips and Tricks for Surgery and Postoperative Management. *Life* 2022;12. <https://doi.org/10.3390/life12081193>.
- [112] Ferretti S, Dell’oglio P, Ciavarella D, Galfano A, Schips L, Marchioni M. Retzius-Sparing Robotic-Assisted Prostatectomy: Technical Challenges for Surgeons and Key Prospective Refinements. *Research and Reports in Urology* 2023;15:541–52. <https://doi.org/10.2147/RRU.S372803>.
- [113] Ferretti S, Mercinelli C, Marandino L, Litterio G, Marchioni M, Schips L. Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs. *Research and Reports in Urology* 2023;15:243–59. <https://doi.org/10.2147/RRU.S385257>.
- [114] Ferriero M, Mastroianni R, De Nunzio C, Cindolo L, Calabrò F, Tema G, et al. Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort. *World Journal of Urology* 2020;38:1757–64. <https://doi.org/10.1007/s00345-019-02974-6>.
- [115] Ferro M, Barone B, Crocetto F, Lucarelli G, Busetto GM, Del Giudice F, et al. Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations* 2022;40:490.e13-490.e20. <https://doi.org/10.1016/j.urolonc.2022.05.016>.
- [116] Ferro M, Chiuidea S, Vartolomei MD, Bove P, Porreca A, Busetto GM, et al. Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. *Clinical Genitourinary Cancer* 2024;22:27–37. <https://doi.org/10.1016/j.clgc.2023.08.001>.
- [117] Ferro M, Crocetto F, Barone B, del Giudice F, Maggi M, Lucarelli G, et al. Artificial intelligence and radiomics in evaluation of kidney lesions: a comprehensive literature review. *Therapeutic Advances in Urology* 2023;15. <https://doi.org/10.1177/17562872231164803>.
- [118] Ferro M, Crocetto F, Tataru S, Barone B, Dolce P, Lucarelli G, et al. Predictors

- of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis. *Clinical Genitourinary Cancer* 2023;21:574–83. <https://doi.org/10.1016/j.clgc.2023.05.017>.
- [119] Ferro M, Del Giudice F, Carrieri G, Busetto GM, Cormio L, Hurle R, et al. The impact of sars-cov-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: A retrospective multi-institutional cohort analysis. *Cancers* 2021;13. <https://doi.org/10.3390/cancers13215276>.
- [120] Ferro M, Di Mauro M, Cimino S, Morgia G, Lucarelli G, Abu Farhan AR, et al. Systemic combining inflammatory score (SCIS): A new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. *Translational Andrology and Urology* 2021;10:626–35. <https://doi.org/10.21037/TAU-20-1272>.
- [121] Ferro M, Marchioni M, Lucarelli G, Vartolomei MD, Soria F, Terracciano D, et al. Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study. *Minerva Urology and Nephrology* 2022;73:796–802. <https://doi.org/10.23736/S2724-6051.20.04076-X>.
- [122] Ferro M, Musi G, Marchioni M, Maggi M, Veccia A, Del Giudice F, et al. Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects. *International Journal of Molecular Sciences* 2023;24. <https://doi.org/10.3390/ijms24054615>.
- [123] Ferro M, Tătaru OS, Musi G, Lucarelli G, Abu Farhan AR, Cantiello F, et al. Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy. *Diagnostics* 2022;12. <https://doi.org/10.3390/diagnostics12030586>.
- [124] Ficarra V, Galfano A, Guillé F, Schips L, Tostain J, Mejean A, et al. A New Staging System for Locally Advanced (pT3-4) Renal Cell Carcinoma: A Multicenter European Study Including 2,000 Patients. *Journal of Urology* 2007;178:418–24. <https://doi.org/10.1016/j.juro.2007.03.104>.
- [125] Ficarra V, Guillé F, Schips L, De La Taille A, Galetti TP, Tostain J, et al. Proposal for revision of the TNM classification system for renal cell carcinoma. *Cancer* 2005;104:2116–23. <https://doi.org/10.1002/cncr.21465>.
- [126] Ficarra V, Schips L, Guillé F, Li G, De La Taille A, Galetti TP, et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. *Cancer* 2005;104:968–74. <https://doi.org/10.1002/cncr.21254>.
- [127] Ficarra V, Secco S, Fracalanza S, Novara G, Gidaro S, Cindolo L, et al. Expanding indication for elective nephron-sparing surgery in renal cell carcinoma. *Archivio Italiano Di Urologia e Andrologia* 2009;81:86–90.
- [128] Gacci M, Marchioni M, de Francesco P, Natoli C, Calabrò F, Losanno T, et al. Enzalutamide in patients with castration-resistant prostate cancer: Retrospective, multicenter, real life study. *Minerva Urology and Nephrology* 2021;73:489–97. <https://doi.org/10.23736/S2724-6051.20.03723-6>.
- [129] Gallo F, Sforza S, Luciani L, Mattevi D, Barzaghi P, Mari A, et al. Simultaneous robotic partial nephrectomy for bilateral renal masses. *World Journal of Urology* 2022;40:1005–10. <https://doi.org/10.1007/s00345-021-03919-8>.
- [130] Ghahhari J, D’Orta C, Rizzoli A, Marchioni M, Primiceri GI, De Francesco P, et al. Monocenter Experience with 532 Nm-Laser Photoselective-Vaporization of the Prostate by GreenLight XPS Laser: Is It Really an Endourological Joker Card? *Surgical Technology International* 2018;32:164–72.
- [131] Ghahhari J, Marchioni M, Spiess PE, Chipollini JJ, Nyirády P, Varga J, et al. Radical penectomy, a compromise for life: Results from the PECAD study.

- Translational Andrology and Urology 2020;9:1306–13.
<https://doi.org/10.21037/tau.2020.04.04>.
- [132] Ghahhari J, Nunzio CDE, Lombardo R, Tubaro A, Brasseti A, Francesco PDE, et al. Efficacy and efficiency of Green-Light XPS 180-watt laser system for benign prostatic enlargement in patients treated with 5 α -reductase inhibitors. *European Review for Medical and Pharmacological Sciences* 2021;25:4527–34.
https://doi.org/10.26355/eurev_202107_26245.
- [133] Gidaro S, Cindolo L, Lipsky K, Zigeuner R, Schips L. Efficacy and safety of the haemostasis achieved by Vivostat System during laparoscopic partial nephrectomy. *Archivio Italiano Di Urologia e Andrologia* 2009;81:223–6.
- [134] Gidaro S, Cindolo L, Tamburro FR, Schips L. First Italian experience in single incision laparoscopic nephrectomy. Assessing and overcoming new challenges. *Archivio Italiano Di Urologia e Andrologia* 2010;82:187–92.
- [135] Gidaro S, Cindolo L, Tamburro FR, Longo N, Mirone V, Forgione A, et al. First Italian experience in single-incision laparoscopic nephrectomy. *Surgical Technology International* 2010;20:47–52.
- [136] Gidaro S, Schips L, Cindolo L, Ziguener R. Laparoscopic nephrectomy for complete renal Infarction due to post traumatic renal artery thrombosis. *Archivio Italiano Di Urologia e Andrologia* 2008;80:79–81.
- [137] Greco F, Autorino R, Rha KH, Derweesh I, Cindolo L, Richstone L, et al. Laparoendoscopic single-site partial nephrectomy: A multi-institutional outcome analysis. *European Urology* 2013;64:314–22.
<https://doi.org/10.1016/j.eururo.2013.01.025>.
- [138] Greco F, Cindolo L, Autorino R, Micali S, Stein RJ, Bianchi G, et al. Laparoendoscopic single-site upper urinary tract surgery: Assessment of postoperative complications and analysis of risk factors. *European Urology* 2012;61:510–6. <https://doi.org/10.1016/j.eururo.2011.08.032>.
- [139] Greco F, Marchioni M, Esperto F, Papalia R, Schips L, Scarpa RM. How targeted therapy influence renal surgery for renal cell carcinoma. *Current Drug Targets* 2020;21:1550–7. <https://doi.org/10.2174/1389450121666200704150933>.
- [140] Gruber H, Humer-Fuchs U, Hechtl W, Schips L, Beham A, Pummer K. Dedifferentiated liposarcoma of the spermatic cord. A case report. *Acta Urologica Italica* 1998;12:283–5.
- [141] Habermann H, Benesch M, Schips L, Pummer K, Ratschek M, Uggowitz MM, et al. Findings and clinical course of a localized primitive peripheral neuroectodermal tumor of the kidney. *Urologia Internationalis* 2003;71:319–21.
<https://doi.org/10.1159/000072686>.
- [142] Hutterer GC, Patard J-J, Jeldres C, Perrotte P, De La Taille A, Salomon L, et al. Patients with distant metastases from renal cell carcinoma can be accurately identified: External validation of a new nomogram. *BJU International* 2008;101:39–43. <https://doi.org/10.1111/j.1464-410X.2007.07170.x>.
- [143] Hutterer GC, Patard J-J, Perrotte P, Ionescu C, De La Taille A, Salomon L, et al. Patients with renal cell carcinoma nodal metastases can be accurately identified: External validation of a new nomogram. *International Journal of Cancer* 2007;121:2556–61. <https://doi.org/10.1002/ijc.23010>.
- [144] Kaouk JH, Autorino R, Kim FJ, Han DH, Lee SW, Yinghao S, et al. Laparoendoscopic single-site surgery in urology: Worldwide multi-institutional analysis of 1076 cases. *European Urology* 2011;60:998–1005.
<https://doi.org/10.1016/j.eururo.2011.06.002>.
- [145] Kaouk JH, Autorino R, Kim FJ, Han DH, Lee SW, Yinghao S, et al. Laparoendoscopic Single-site Surgery in Urology: Worldwide Multi-institutional Analysis of 1076 Cases. *International Braz J Urol* 2011;37:662.
<https://doi.org/10.1590/S1677-55382011000500017>.
- [146] Karakiewicz PI, Hutterer GC, Trinh Q-D, Pantuck AJ, Klatte T, Lam JS, et al.

- Unclassified renal cell carcinoma: An analysis of 85 cases. *BJU International* 2007;100:802–8. <https://doi.org/10.1111/j.1464-410X.2007.07148.x>.
- [147] Karakiewicz PI, Jeldres C, Suardi N, Hutterer GC, Perrotte P, Capitanio U, et al. Age at diagnosis is a determinant factor of renal cell carcinomaspecific survival in patients treated with nephrectomy. *Journal of the Canadian Urological Association* 2008;2:610–7. <https://doi.org/10.5489/cuaj.978>.
- [148] Karakiewicz PI, Trinh Q-D, Bhojani N, Bensalah K, Salomon L, de la Taille A, et al. Renal Cell Carcinoma with Nodal Metastases in the Absence of Distant Metastatic Disease: Prognostic Indicators of Disease-Specific Survival. *European Urology* 2007;51:1616–24. <https://doi.org/10.1016/j.eururo.2006.12.015>.
- [149] Karakiewicz PI, Trinh Q-D, Rioux-Leclercq N, de la Taille A, Novara G, Tostain J, et al. Collecting Duct Renal Cell Carcinoma: A Matched Analysis of 41 Cases. *European Urology* 2007;52:1140–6. <https://doi.org/10.1016/j.eururo.2007.01.070>.
- [150] Klatte T, Patard J-J, Goel RH, Kleid MD, Guille F, Lobel B, et al. Prognostic Impact of Tumor Size on pT2 Renal Cell Carcinoma: An International Multicenter Experience. *Journal of Urology* 2007;178:35–40. <https://doi.org/10.1016/j.juro.2007.03.046>.
- [151] Lam JS, Klatte T, Patard J-J, Goel RH, Guille F, Lobel B, et al. Prognostic Relevance of Tumour Size in T3a Renal Cell Carcinoma: A Multicentre Experience. *European Urology* 2007;52:155–62. <https://doi.org/10.1016/j.eururo.2007.01.106>.
- [152] Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation? *Journal of Clinical Pathology* 2004;57:773–5. <https://doi.org/10.1136/jcp.2003.015743>.
- [153] Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. CD10 is a diagnostic and prognostic marker in renal malignancies. *Histopathology* 2004;45:460–7. <https://doi.org/10.1111/j.1365-2559.2004.01982.x>.
- [154] Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: A systematic immunohistochemical analysis of 188 cases. *Modern Pathology* 2004;17:180–8. <https://doi.org/10.1038/modpathol.3800032>.
- [155] Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Steroid hormone receptor expression in renal cell carcinoma: An immunohistochemical analysis of 182 tumors. *Journal of Urology* 2004;171:611–4. <https://doi.org/10.1097/01.ju.0000108040.14303.c2>.
- [156] Langner C, Ratschek M, Tsybrovskyy O, Schips L, Zigeuner R. P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. *Journal of Histochemistry and Cytochemistry* 2003;51:1097–9. <https://doi.org/10.1177/002215540305100813>.
- [157] Langner C, Wegscheider BJ, Ratschek M, Schips L, Zigeuner R. Keratin immunohistochemistry in renal cell carcinoma subtypes and renal oncocytomas: A systematic analysis of 233 tumors. *Virchows Archiv* 2004;444:127–34. <https://doi.org/10.1007/s00428-003-0948-2>.
- [158] Lapini A, Minervini A, Masala A, Schips L, Pycha A, Cindolo L, et al. A comparison of hexaminolevulinate (Hexvix®) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: Results of the HeRo observational study. *Surgical Endoscopy* 2012;26:3634–41. <https://doi.org/10.1007/s00464-012-2387-0>.
- [159] Larcher A, Wallis CJD, Pavan N, Porpiglia F, Takagi T, Tanabe K, et al. Outcomes of minimally invasive partial nephrectomy among very elderly patients: Report from the resurge collaborative international database. *Central European Journal of Urology* 2020;73:273–9. <https://doi.org/10.5173/cej.2020.0179>.
- [160] Lipsky K, Zigeuner R, Zischka M, Schips L, Pummer K, Rehak P, et al.

- Selenium levels of patients with newly diagnosed prostate cancer compared with control group. *Urology* 2004;63:912–6. <https://doi.org/10.1016/j.urology.2003.12.028>.
- [161] Marchioni M, Amparore D, Magli IA, Bertolo R, Carbonara U, Erdem S, et al. Potential benefit of lymph node dissection during radical nephrectomy for kidney cancer: A review and critical analysis of current literature. *Asian Journal of Urology* 2022;9:215–26. <https://doi.org/10.1016/j.ajur.2022.03.007>.
- [162] Marchioni M, Bandini M, Pompe RS, Tian Z, Martel T, Kapoor A, et al. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. *International Urology and Nephrology* 2017;49:2143–9. <https://doi.org/10.1007/s11255-017-1703-y>.
- [163] Marchioni M, Bandini M, Pompe RS, Martel T, Tian Z, Shariat SF, et al. The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT2-3 non-metastatic renal cell carcinoma treated with radical nephrectomy. *BJU International* 2018;121:383–92. <https://doi.org/10.1111/bju.14024>.
- [164] Marchioni M, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, et al. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. *European Urology Focus* 2019;5:488–96. <https://doi.org/10.1016/j.euf.2017.11.012>.
- [165] Marchioni M, Berardinelli F, De Nunzio C, Spiess P, Porpiglia F, Schips L, et al. New insight in penile cancer. *Minerva Urologica e Nefrologica* 2018;70:559–69. <https://doi.org/10.23736/S0393-2249.18.03215-0>.
- [166] Marchioni M, Berardinelli F, Zhang C, Simone G, Uzzo RG, Capitanio U, et al. Effect of Obesity and Overweight Status on Complications and Survival after Minimally Invasive Kidney Surgery in Patients with Clinical T2-4 Renal Masses. *Journal of Endourology* 2020;34:289–97. <https://doi.org/10.1089/end.2019.0604>.
- [167] Marchioni M, Cheaib JG, Takagi T, Pavan N, Antonelli A, Everaerts W, et al. Active surveillance for small renal masses in elderly patients does not increase overall mortality rates compared to primary intervention: a propensity score weighted analysis. *Minerva Urology and Nephrology* 2022;73:781–8. <https://doi.org/10.23736/S2724-6051.20.03785-6>.
- [168] Marchioni M, Cindolo L, Autorino R, Primiceri G, Arcaniolo D, De Sio M, et al. High Neutrophil-to-lymphocyte Ratio as Prognostic Factor in Patients Affected by Upper Tract Urothelial Cancer: A Systematic Review and Meta-analysis. *Clinical Genitourinary Cancer* 2017;15:343–349.e1. <https://doi.org/10.1016/j.clgc.2016.12.027>.
- [169] Marchioni M, Cindolo L, Di Nicola M, Schips L, De Sio M, Lima E, et al. Major Acute Cardiovascular Events After Transurethral Prostate Surgery: A Population-based Analysis. *Urology* 2019;131:196–203. <https://doi.org/10.1016/j.urology.2019.05.014>.
- [170] Marchioni M, de Francesco P, Campi R, Carbonara U, Ferro M, Schips L, et al. Current management of radiation cystitis after pelvic radiotherapy: a systematic review. *Minerva Urology and Nephrology* 2022;74:281–91. <https://doi.org/10.23736/S2724-6051.21.04539-0>.
- [171] Marchioni M, de Francesco P, Castellucci R, Papalia R, Sarikaya S, Gomez Rivas J, et al. Management of erectile dysfunction following robot-assisted radical prostatectomy: a systematic review. *Minerva Urologica e Nefrologica* 2020;72:543–54. <https://doi.org/10.23736/S0393-2249.20.03780-7>.
- [172] Marchioni M, Di Nicola M, Primiceri G, Novara G, Castellan P, Paul AK, et al. New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis. *Journal of Urology* 2020;203:751–9. <https://doi.org/10.1097/JU.0000000000000636>.
- [173] Marchioni M, Harmouch SS, Nazzani S, Bandini M, Preisser F, Tian Z, et al.

- Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. *Cancer Epidemiology* 2018;54:112–8. <https://doi.org/10.1016/j.canep.2018.04.006>.
- [174] Marchioni M, Marandino L, Amparore D, Berardinelli F, Mascitti M, Ferro M, et al. Factors influencing survival in metastatic castration-resistant prostate cancer therapy. *Expert Review of Anticancer Therapy* 2022. <https://doi.org/10.1080/14737140.2022.2114458>.
- [175] Marchioni M, Martel T, Bandini M, Pompe RS, Tian Z, Kapoor A, et al. Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1–2 N0 M0 renal cell carcinoma. *World Journal of Urology* 2017;35:1899–905. <https://doi.org/10.1007/s00345-017-2082-9>.
- [176] Marchioni M, Nazzani S, Preisser F, Bandini M, Tian Z, Kapoor A, et al. The effect of institution teaching status on perioperative outcomes after robotic partial or radical nephrectomy. *Journal of Endourology* 2018;32:621–9. <https://doi.org/10.1089/end.2018.0025>.
- [177] Marchioni M, Preisser F, Bandini M, Nazzani S, Tian Z, Kapoor A, et al. Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. *European Urology Focus* 2019;5:467–73. <https://doi.org/10.1016/j.euf.2018.01.007>.
- [178] Marchioni M, Primiceri G, Castellan P, Schips L, Mantica G, Chapple C, et al. Conservative management of urinary incontinence following robot-assisted radical prostatectomy. *Minerva Urologica e Nefrologica* 2020;72:555–62. <https://doi.org/10.23736/S0393-2249.20.03782-0>.
- [179] Marchioni M, Primiceri G, Cindolo L, Hampton LJ, Grob MB, Guruli G, et al. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. *BJU International* 2017;120:313–9. <https://doi.org/10.1111/bju.13935>.
- [180] Marchioni M, Primiceri G, Delli Pizzi A, Basilico R, Berardinelli F, Mincuzzi E, et al. Could Bladder Multiparametric MRI Be Introduced in Routine Clinical Practice? Role of the New VI-RADS Score: Results From a Prospective Study. *Clinical Genitourinary Cancer* 2020;18:409–415.e1. <https://doi.org/10.1016/j.clgc.2020.03.002>.
- [181] Marchioni M, Primiceri G, Ingrosso M, Filograna R, Castellan P, De Francesco P, et al. The Clinical Use of the Neutrophil to Lymphocyte Ratio (NLR) in Urothelial Cancer: A Systematic Review. *Clinical Genitourinary Cancer* 2016;14:473–84. <https://doi.org/10.1016/j.clgc.2016.04.008>.
- [182] Marchioni M, Primiceri G, Vecchia A, Di Nicola M, Carbonara U, Crocero S, et al. Transurethral prostate surgery in prostate cancer patients: A population-based comparative analysis of complication and mortality rates. *Asian Journal of Urology* 2024;11:48–54. <https://doi.org/10.1016/j.ajur.2022.05.008>.
- [183] Marchioni M, Rivas JG, Autran A, Socarras M, Albisinni S, Ferro M, et al. Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art. *Current Urology Reports* 2021;22. <https://doi.org/10.1007/s11934-021-01050-0>.
- [184] Marchioni M, Schips L. Editorial Comment. *The Journal of Urology* 2021;205:398–9. <https://doi.org/10.1097/JU.0000000000001370.01>.
- [185] Marchioni M, Schips L, Greco F, Frattini A, Neri F, Ruggera L, et al. Perioperative major acute cardiovascular events after 180-W GreenLight laser photoselective vaporization of the prostate. *International Urology and Nephrology* 2018;50:1955–62. <https://doi.org/10.1007/s11255-018-1968-9>.
- [186] Marchioni M, Sountoulides P, Bada M, Rapisarda S, De Nunzio C, Tamburro FR, et al. Abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a systematic review of ‘real-life’ studies. *Therapeutic Advances in Urology* 2018;10:305–15. <https://doi.org/10.1177/1756287218786160>.
- [187] Marchioni M, Sountoulides P, Furlan M, Mir MC, Aretano L, Rubio-Briones J,

- et al. Management of local recurrence after radical nephrectomy: surgical removal with or without systemic treatment is still the gold standard. Results from a multicenter international cohort. *International Urology and Nephrology* 2021;53:2273–80. <https://doi.org/10.1007/s11255-021-02966-9>.
- [188] Mari A, Campi R, Schiavina R, Amparore D, Antonelli A, Artibani W, et al. Nomogram for predicting the likelihood of postoperative surgical complications in patients treated with partial nephrectomy: a prospective multicentre observational study (the RECORd 2 project). *BJU International* 2019;124:93–102. <https://doi.org/10.1111/bju.14680>.
- [189] Mascia M, Villano C, De Francesco V, Schips L, Marchioni M, Cindolo L. Efficacy and Safety of the $^{64}\text{Cu}(\text{II})\text{Cl}_2\text{PET/CT}$ for Urological Malignancies: Phase IIa Clinical Study. *Clinical Nuclear Medicine* 2021;46:443–8. <https://doi.org/10.1097/RLU.0000000000003658>.
- [190] May M, Aziz A, Zigeuner R, Chromecki T, Cindolo L, Schips L, et al. Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: An analysis of the multicenter CORONA database. *World Journal of Urology* 2013;31:1073–80. <https://doi.org/10.1007/s00345-013-1071-x>.
- [191] May M, Cindolo L, Zigeuner R, De Cobelli O, Rocco B, De Nunzio C, et al. Results of a comparative study analyzing octogenarians with renal cell carcinoma in a competing risk analysis with patients in the seventh decade of life. *Urologic Oncology: Seminars and Original Investigations* 2014;32:1252–8. <https://doi.org/10.1016/j.urolonc.2014.04.013>.
- [192] May M, Zigeuner R, Aziz A, Cindolo L, Gilfrich C, Schips L, et al. Postoperative prognosis of chromophobic renal cell carcinoma. Comparative analysis of the multinational CORONA database. *Urologe - Ausgabe A* 2014;53:228–35. <https://doi.org/10.1007/s00120-013-3237-y>.
- [193] Mearini E, Schips L, Sèbe P. Editorial: History, advantages, complications, and limits of minimally invasive urologic pelvic surgery. *Frontiers in Surgery* 2023;10. <https://doi.org/10.3389/fsurg.2023.1260951>.
- [194] Micali S, Sighinolfi MC, Iseppi A, Morini E, Calcagnile T, Benedetti M, et al. Initial Experience and Evaluation of a Nomogram for Outcome Prediction in Management of Medium-sized (1–2 cm) Kidney Stones. *European Urology Focus* 2022;8:276–82. <https://doi.org/10.1016/j.euf.2020.12.012>.
- [195] Mir MC, Pavan N, Capitanio U, Antonelli A, Derweesh I, Rodriguez-Faba O, et al. Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). *World Journal of Urology* 2020;38:151–8. <https://doi.org/10.1007/s00345-019-02665-2>.
- [196] Monti M, Lunardini S, Magli IA, Campi R, Primiceri G, Berardinelli F, et al. Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature. *Biomedicines* 2022;10. <https://doi.org/10.3390/biomedicines10061287>.
- [197] Neri F, Berardinelli F, Cindolo L, Sountoulides P, Pellegrini F, Mirone V, et al. Is a single-site laparoendoscopic approach a real surgical advancement for the management of small renal masses? *Surgical Technology International* 2013;23:29–33.
- [198] Neri F, Cindolo L, Gidaro S, Schips L. [The LESS (Laparo-endoscopic Single-Site) procedure in urology. Technical and clinical aspects]. *Urologia* 2010;77:13–20. <https://doi.org/10.1177/039156031007700103>.
- [199] Orsini A, Bignante G, Lasorsa F, Bologna E, Mossack SM, Pacini M, et al. Urachal Carcinoma: Insights From a National Database. *Clinical Genitourinary Cancer* 2024;22. <https://doi.org/10.1016/j.clgc.2024.102175>.
- [200] Orsini A, Digiacomo A, Ferretti S, Tamborino F, Basconi M, Cicchetti R, et al. Robotic bladder diverticulectomy with concurrent management of bladder outlet obstruction: A choice to consider. *Urologia Journal* 2024.

- <https://doi.org/10.1177/03915603241258107>.
- [201] Orsini A, Ferretti S, Tamborino F, Cicchetti R, Ciavarella D, Seccia B, et al. Mastering bladder paraganglioma for optimal treatment: a case report of robot-assisted surgery. *Therapeutic Advances in Urology* 2024;16. <https://doi.org/10.1177/17562872241249603>.
- [202] Pavan N, Autorino R, Lee H, Porpiglia F, Sun Y, Greco F, et al. Impact of novel techniques on minimally invasive adrenal surgery: trends and outcomes from a contemporary international large series in urology. *World Journal of Urology* 2016;34:1473–9. <https://doi.org/10.1007/s00345-016-1791-9>.
- [203] Pirozzi L, Sountoulide P, Castellan P, Presicce F, Lombardo R, Romero M, et al. Current pharmacological treatment for male LUTS due to BPH: Dutasteride or finasteride? *Current Drug Targets* 2015;16:1165–71. <https://doi.org/10.2174/1389450116666150518101617>.
- [204] Porpiglia F, Mari A, Amparore D, Fiori C, Antonelli A, Artibani W, et al. Transperitoneal vs retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large multi-institutional cohort (The RECORD 2 Project). *Surgical Endoscopy* 2021;35:4295–304. <https://doi.org/10.1007/s00464-020-07919-4>.
- [205] Porreca A, Di Nicola M, Lucarelli G, Dorin VM, Soria F, Terracciano D, et al. Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional database. *Urologic Oncology: Seminars and Original Investigations* 2024;42:69.e17–69.e25. <https://doi.org/10.1016/j.urolonc.2024.01.001>.
- [206] Primiceri G, Castellan P, Marchioni M, Schips L, Cindolo L. Bladder Neck Contracture After Endoscopic Surgery for Benign Prostatic Obstruction: Incidence, Treatment, and Outcomes. *Current Urology Reports* 2017;18. <https://doi.org/10.1007/s11934-017-0723-6>.
- [207] Procopio G, Chiuri VE, Giordano M, Mantini G, Maisano R, Bordonaro R, et al. Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABlitude study. *Therapeutic Advances in Medical Oncology* 2020;12. <https://doi.org/10.1177/1758835920968725>.
- [208] Procopio G, Chiuri VE, Giordano M, Alitto AR, Maisano R, Bordonaro R, et al. Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABlitude study. *ESMO Open* 2022;7. <https://doi.org/10.1016/j.esmoop.2022.100431>.
- [209] Proietti S, Marchioni M, Eisner BH, Lucianò R, Saitta G, Rodríguez-Socarrás ME, et al. Conservative treatment of upper urinary tract carcinoma in patients with imperative indications. *Minerva Urology and Nephrology* 2021;73:245–52. <https://doi.org/10.23736/S2724-6051.20.03710-8>.
- [210] Proietti S, Marchioni M, Oo MM, Scalia R, Gisone S, Monroy RE, et al. Flexible Ureteroscopic Lithotripsy with the Pulsed Thulium:Yttrium Aluminum Garnet Laser Thulio: Preliminary Results from a Prospective Study. *European Urology Open Science* 2024;67:77–83. <https://doi.org/10.1016/j.euros.2024.07.114>.
- [211] Pugliese D, Cindolo L, Acampora A, Porreca A, Schips L. Effectiveness of a novel oral combination of D-Mannose, pomegranate extract, prebiotics and probiotics in the treatment of acute cystitis in women. *Archivio Italiano Di Urologia e Andrologia* 2020;92:34–8. <https://doi.org/10.4081/aiua.2020.1.34>.
- [212] Pummer K, Stettner H, Augustin H, Zigeuner R, Habermann H, Schips L, et al. The use of body mass index to predict pathological stage in patients with clinically localized prostate cancer. *Onkologie* 2007;30:489–94. <https://doi.org/10.1159/000106096>.
- [213] Rane A, Cindolo L, Schips L, de Sio M, Autorino R. Laparoendoscopic single

- site (LESS) adrenalectomy: Technique and outcomes. *World Journal of Urology* 2012;30:597–604. <https://doi.org/10.1007/s00345-011-0678-z>.
- [214] Reale G, Marchioni M, Altieri V, Greco F, de Nunzio C, Destefanis P, et al. Operative profile, safety and functional outcomes after GreenLight laser prostate surgery: results from a 12 months follow-up multicenter Italian cohort analyses. *Minerva Urologica e Nefrologica* 2020;72:622–8. <https://doi.org/10.23736/S0393-2249.20.03597-3>.
- [215] Russo MV, Esposito S, Tupone MG, Manzoli L, Airoidi I, Pompa P, et al. SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis. *Oncotarget* 2016;7:12372–85. <https://doi.org/10.18632/oncotarget.6029>.
- [216] Sansone A, Frangione V, Lanzarotti A, Cocci A, Ceruti C, De Sio M, et al. Effect of the new 75-mg orodispersible film of sildenafil on erection and sexual quality of life: insights from an observational study. *Sexual Medicine* 2023;11. <https://doi.org/10.1093/sexmed/qfac007>.
- [217] Schiavina R, Mari A, Bianchi L, Amparore D, Antonelli A, Artibani W, et al. Predicting positive surgical margins in partial nephrectomy: A prospective multicentre observational study (the RECORd 2 project). *European Journal of Surgical Oncology* 2020;46:1353–9. <https://doi.org/10.1016/j.ejso.2020.01.022>.
- [218] Schips L, Augustin H, Zigeuner RE, Gallé G, Habermann H, Trummer H, et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? *Urology* 2002;59:220–3. [https://doi.org/10.1016/S0090-4295\(01\)01522-9](https://doi.org/10.1016/S0090-4295(01)01522-9).
- [219] Schips L, Berardinelli F, Neri F, Tamburro FR, Cindolo L. Laparoendoscopic single-site partial nephrectomy without ischemia for very small, exophytic renal masses: Surgical details and functional outcomes. *European Urology* 2013;63:759–65. <https://doi.org/10.1016/j.eururo.2012.08.008>.
- [220] Schips L, Cindolo L. Editorial Comment on: Metastin Inhibits Migration and Invasion of Renal Cell Carcinoma with Overexpression of Metastin Receptor. *European Urology* 2009;55:449–50. <https://doi.org/10.1016/j.eururo.2008.02.049>.
- [221] Schips L, Cindolo L. Editorial Comment on: Single-Port Laparoscopic and Robotic Partial Nephrectomy. *European Urology* 2009;55:1169–70. <https://doi.org/10.1016/j.eururo.2008.12.030>.
- [222] Schips L, Colombo T, Koshisorur G, Trummer H, Hubmer G. Source of reactive oxygen species in varicocele patients. *Medical Science Research* 1999;27:677–9.
- [223] Schips L, Dalpiaz O, Cestari A, Lipsky K, Gidaro S, Zigeuner R, et al. Autologous Fibrin Glue Using the Vivostat System for Hemostasis in Laparoscopic Partial Nephrectomy. *European Urology* 2006;50:801–5. <https://doi.org/10.1016/j.eururo.2006.03.010>.
- [224] Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P, et al. Serum Levels of Vascular Endothelial Growth Factor (VEGF) and Endostatin in Renal Cell Carcinoma Patients Compared to a Control Group. *European Urology* 2007;51:168–74. <https://doi.org/10.1016/j.eururo.2006.06.026>.
- [225] Schips L, Lipsky K, Hebel P, Hutterer G, Gidaro S, Petritsch PH, et al. Laparoscopic fenestration of lymphoceles after kidney transplantation with diaphanoscopy guidance. vol. 66, 2005, p. 185–7. <https://doi.org/10.1016/j.urology.2005.02.020>.
- [226] Schips L, Lipsky K, Zigeuner R, Salfellner M, Winkler S, Langner C, et al. Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: A single-center experience of 683 patients. *Urology* 2003;62:1024–8. [https://doi.org/10.1016/S0090-4295\(03\)00763-5](https://doi.org/10.1016/S0090-4295(03)00763-5).
- [227] Schips L, Lipsky K, Zigeuner R, Gidaro S, Salfellner M, Rehak P, et al. Does overweight impact on the prognosis of patients with renal cell carcinoma? A single

- center experience of 683 patients. *Journal of Surgical Oncology* 2004;88:57–61. <https://doi.org/10.1002/jso.20139>.
- [228] Schips L, Ratschek M, Gallé G, Zigeuner R, Trummer H, Petritsch PH, et al. Angiomyolipoma with a caval thrombus. *Urologia Internationalis* 2003;70:332–4. <https://doi.org/10.1159/000070147>.
- [229] Schips L, Volpe A. CXCR4 and renal cancer: From lab to bedside. *Cell Cycle* 2010;9:4785. <https://doi.org/10.4161/cc.9.24.14165>.
- [230] Schips L, Zigeuner R, Lipsky K, Quehenberger F, Salfellner M, Winkler S, et al. Do patients with a higher body mass index have a greater risk of advanced-stage renal cell carcinoma? *Urology* 2003;62:437–41. [https://doi.org/10.1016/S0090-4295\(03\)00380-7](https://doi.org/10.1016/S0090-4295(03)00380-7).
- [231] Schips L, Zigeuner R, Ratschek M, Rehak P, Rüschhoff J, Langner C. Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. *American Journal of Clinical Pathology* 2004;122:931–7. <https://doi.org/10.1309/G7PY0RE7T86HHQYV>.
- [232] Schips L, Zigeuner RE, Langner C, Mayer R, Pummer K, Hubmer G. Metastasis of an ascending colon carcinoma in the prostate 10 years after hemicolectomy. *Journal of Urology* 2002;168:641–2. [https://doi.org/10.1016/S0022-5347\(05\)64701-5](https://doi.org/10.1016/S0022-5347(05)64701-5).
- [233] Simone G, De Nunzio C, Ferriero M, Cindolo L, Brookman-May S, Papalia R, et al. Trends in the use of partial nephrectomy for cT1 renal tumors: Analysis of a 10-yr European multicenter dataset. *European Journal of Surgical Oncology* 2016;42:1729–35. <https://doi.org/10.1016/j.ejso.2016.03.022>.
- [234] Sountoulides P, Neri F, Bellocci R, Schips L, Cindolo L. Splenogonadal fusion mimicking a testis tumor. *Journal of Postgraduate Medicine* 2014;60:202–4. <https://doi.org/10.4103/0022-3859.132350>.
- [235] Springer C, Greco F, Autorino R, Rha KH, Derweesh I, Cindolo L, et al. Analysis of oncological outcomes and renal function after laparoendoscopic single-site (LESS) partial nephrectomy: A multi-institutional outcome analysis. *BJU International* 2014;113:266–74. <https://doi.org/10.1111/bju.12376>.
- [236] Springer C, Greco F, Autorino R, Rha KH, Derweesh I, Cindolo L, et al. Erratum: Analysis of oncological outcomes and renal function after laparoendoscopic single-site (LESS) partial nephrectomy: A multi-institutional outcome analysis. (*BJU International* (2014) 113 (266–74)). *BJU International* 2015;115:E12. <https://doi.org/10.1111/bju.13095>.
- [237] Tafuri A, Marchioni M, Cerrato C, Mari A, Tellini R, Odorizzi K, et al. Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium). *World Journal of Urology* 2022;40:2771–9. <https://doi.org/10.1007/s00345-022-04156-3>.
- [238] Tamborino F, Cicchetti R, Mascitti M, Litterio G, Orsini A, Ferretti S, et al. Pathophysiology and Main Molecular Mechanisms of Urinary Stone Formation and Recurrence. *International Journal of Molecular Sciences* 2024;25. <https://doi.org/10.3390/ijms25053075>.
- [239] Tamburro FR, Castellan P, Neri F, Berardinelli F, Bada M, Sountoulides P, et al. Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience. *Urologia* 2018;85:163–8. <https://doi.org/10.1177/0391560318759258>.
- [240] Verhoest G, Veillard D, Guillé F, Taille ADL, Salomon L, Abbou CC, et al. Relationship between Age at Diagnosis and Clinicopathologic Features of Renal Cell Carcinoma. *European Urology* 2007;51:1298–305. <https://doi.org/10.1016/j.eururo.2006.11.056>.
- [241] Wolff I, May M, Hoschke B, Zigeuner R, Cindolo L, Hutterer G, et al. Do we need new high-risk criteria for surgically treated renal cancer patients to improve the

outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database. *European Journal of Surgical Oncology* 2016;42:744–50. <https://doi.org/10.1016/j.ejso.2016.01.009>.

[242] Yim K, Aron M, Rha KH, Simone G, Minervini A, Challacombe B, et al. Outcomes of Robot-assisted Partial Nephrectomy for Clinical T3a Renal Masses: A Multicenter Analysis. *European Urology Focus* 2021;7:1107–14. <https://doi.org/10.1016/j.euf.2020.10.011>.

[243] Zastrow S, Krabbe L-M, Wolff I, Capitanio U, Klatte T, Ecke T, et al. External validation of a postoperative nomogram for the prediction of disease-specific survival in patients with papillary renal cell carcinoma using a large multicenter database. *International Journal of Clinical Oncology* 2020;25:145–50. <https://doi.org/10.1007/s10147-019-01530-x>.

[244] Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: A systematic analysis of primary and metastatic tumor tissue. *Urology* 2004;63:651–5. <https://doi.org/10.1016/j.urology.2003.11.011>.

[245] Zigeuner R, Schips L, Lipsky K, Auprich M, Salfellner M, Rehak P, et al. Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies. *Urology* 2003;62:883–7. [https://doi.org/10.1016/S0090-4295\(03\)00663-0](https://doi.org/10.1016/S0090-4295(03)00663-0).

[246] Zigeuner RE, Lipsky K, Riedler I, Auprich M, Schips L, Salfellner M, et al. Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. *Urology* 2003;62:451–5. [https://doi.org/10.1016/S0090-4295\(03\)00459-X](https://doi.org/10.1016/S0090-4295(03)00459-X).

ALTRE CAPACITÀ

Capacità Informatiche

Lingue

Dati personali

Microsoft office suite
 Principali browser internet (Internet explorer, Chrome, Mozilla Firefox, Safari)
 Italiano (Madrelingua)
 Inglese (Buona conoscenza e comprensione scritto e parlato)
 Tedesco (Ottima conoscenza e comprensione scritto e parlato)

-omissis-

Chieti, 02/10/2024

(F.to)